⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Figure S7 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity

Ying Kong Xinyue Zhao Zhaofu Wang Siqi Yuan Sheng Chen Shidi Lou Shichao Ma Yunfeng Li Xinghao Wang Yangfeng Ge Guobin Li Hongbing Yang Mengxi Zhao Dandan Li Hailong Zhang Wenfu Tan Juan Wang

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Body weight of mice over the time period of treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kong et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574c1b https://doi.org/10.1158/1535-7163.26423443.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
2Figure S3 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
3Figure S3 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics2025
4Figure S6 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
5Table S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024

Table S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
Table S5 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
Figure S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024